A recent U.S. Department of Health and Human Services advisory opinion, which decided not to impose administrative sanctions regarding a biopharmaceutical company's free genetic testing services, illustrates some unsteady reasoning that could yield different results in other cases, say Dominick DiSabatino and Cynthia Suarez at Sheppard Mullin.